Abstract 475P
Background
Lobectomy had long been the established gold standard curative surgery for early stage lung cancer. With emerging evidence on the non-inferior outcome of segmentectomy, we had been performing segmentectomy on selected stage 1 lung cancer patients in our institution since 2012. It is timely for us to review our experience with segmentectomy in this group of patients.
Methods
We reviewed all the patients in our institution who underwent curative lung resection in a mixed Asian population over a 12-year period between 2006 and 2017. Staging was based on AJCC TNM 6th edition for patients before 2010 and 7th edition for patients after 2010. Only patients with stage 1 lung cancer were included in our study.
Results
269 patients were included in our study. 39 patients (14.5%) underwent segmentectomy, 225 patients (83.6%) underwent lobectomy and 5 patients (1.9%) underwent pneumonectomy. None of the segmentectomy cases had any visceral pleura or lymph node involvement reported on final histology. There was no significant difference in the mean duration of follow up between patients who had segmentectomy (5.37 +/- 2.94 years) and those who had lobectomy and above (6.41 +/- 3.43 years) (p = 0.083). Segmentectomy was associated with a significantly lower recurrence rate (OR 0.19, 95% CI 0.05-0.75) and a 5-year disease free survival of 96.6% compared to 73.1% in lobectomy patients (p = 0.002). The time to recurrence was also longer in segmentectomy patients (mean 4.25 +/- 3.53 years vs 2.78 +/- 2.23 years) but this was not statistically significant (p = 0.371). There was no significance difference in the short term 30-day survival between patients who underwent segmentectomy and lobectomy and above. There was also no significant difference in survival at 1, 3 and 5 years between the 2 groups of patients.
Conclusions
Our study demonstrated good disease-free survival in patients who underwent segmentectomy with no significant differences in overall survival. It is likely that careful selection of patients will produce equally good outcome in segmentectomy patients and this can give us renewed confidence in moving forward with lung preservation surgery for patients with early stage lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract